Middleware and the Clinical Hematology Laboratory
|
|
- Percival West
- 7 years ago
- Views:
Transcription
1 Middleware and the Clinical Hematology Laboratory
2 Balance? Clinical Needs vs. Laboratory Reality TAT Accuracy Resources Costs
3 It doesn t have to be a contest between efficiency and patient care!
4 Today s Outline Background of CBC and diff Verification of the differential count Practice modeling: pre-middleware 5 phases of middleware utilization Automate Rules for Manual Differentials Focus on Patient Safety Issues Enhance Laboratory Effectiveness Support Management Goals Unify Multi-site Practices
5 Evolution of the Complete Blood Count (CBC) Early 1900 s: Counting chambers Colorimetric methods for hemoglobin 1940 s and 1950 s: Wintrobe and the hematocrit tube, MCV, MCH, MCHC 1956: Wallace Coulter and aperture-impedence cell counting method 1970 s: Light scatter cell counting 1980 s & 1990 s: Air- cooled lasers, computers, etc s: Application of immunologic methods 2000 s: Middleware and other software approaches
6 Evolution of the Leukocyte Differential Count (Diff) Early 1900 s: Evolution of manual techniques Early 1970 s: Image capture techniques Hematrak,, IMI Micro 21, LAFIA system, Difffmaster, etc. 1981: Technicon Hemalog D First instrument to perform automated differentials 1983: Coulter Counter Plus IV 3-part differentials 1980 s/90 s: Coulter STKS, Sysmex 9000, Cell Dyne part differentials 2000 s: Image recognition software programs Still in its infancy
7 Why Focus on the CBC and Diff? CBC is the most frequently ordered single laboratory test Highest reimbursed laboratory assay by CMS Used in outpatient and inpatient settings Need 24/7 availability Used as a screening tool for health Opens the door to the patient - looking for possible hematologic, infectious, inflammatory, and oncologic diseases Used specifically to evaluate for a variety of acute and chronic hematologic diseases
8 The Manual Differential The manual differential Is labor intensive Requires both highly skilled and experienced technologists and back-up and availability by pathologists Errors with the manual differential Observer errors Slide distribution errors Sampling errors with a 100 cell count Data entry errors
9 The Automated Differential The automated differential Is geared toward not missing anything Must recognize a wide spectrum of white cell diff abnormalities Lymphoid and myeloid; acute and chronic; pre- and post- therapeutic No single cell type perfectly represents each disease process Can t consistently distinguish between reactive and disease Every instrument technology has its own inherent idiosyncrasies and will over-capture and under- capture particular morphologic abnormalities
10 Manual vs. Automated Diff? The Challenges? Need to identify important abnormal findings while minimizing the time required for either normals or minimal abnormals In other words, maximize the use of automated differentials while minimizing the number of manual differentials The Technology vs. The Art
11 Verification of the Diff: Where? Instrument Auto-verify rules In the Lab Technologist Middleware LIS Auto-verify rules
12 Verification of the Diff: How? Instrument Is geared toward not missing anything Quantitative flags (RBC & WBC) Set by the laboratory Should not be based on normal values Qualitative flags Established by the manufacturer Autoverification at the instrument is dependent on the local patient population Mayo Health System Clinics: 60% auto-release rate U of Michigan and Mayo: 40% auto-release rate
13 Verification of the Diff: How? LIS Dependent on vendor/system Many/Most have rule-writing capabilities Easier for the lab to meet regulatory requirements IT support and back-up Often dependent on non-lab people to write the rules Responsiveness can be at a bureaucratic, glacial pace; non-flexible
14 Verification of the Diff: How? Middleware: Usually purchased from instrument manufacturer Other non-instrument vendors are available Need information from both the instrument and LIS Need to bring middleware vendor, instrument manufacturer, and LIS resources together to understand the interface and what limitations the interface will impose Back-up and IT support is critical for a laboratory. Does the lab have to develop their own expertise?
15 Verification of the Diff: How? Middleware and Mayo Laboratory Hematology Hematology Instrument Interface System (HIIS; Coulter): November 1996 Aqueduct (Orchard Software): July 1999
16 Differential? Instrument auto-verify Scan and release Manual LIS / EMR Minimal abnormal or normal Significant abnormal
17 Practice Modeling Instrument auto-verify Scan and release Manual: Normal/minimal Abnormal (signif) How your practice cases are distributed in these buckets will determine your middleware value. Is your instrument auto-verify at: 80% or 40%? Is your scan and release at: 5% or 30%? Manual differentials: how many have true value added by morphologic review? 5% or 50%?
18 Practice Modeling - Mayo Instrument auto-verify Scan and release Manual: Normal / minimal Manual: Abnormal (significant) Pre-Middleware (1995): 40% 20% 30% 10% Current (2008): 82% 8% 2% 8%
19 Practice Modeling: The Value Equation Middleware Value = Quality (satisfaction, outcomes, safety, and service) Cost Value must drive the process of whether and how middleware should be used in a hematology laboratory.
20 Today s Outline Background of CBC and diff Verification of the differential count Practice modeling: pre-middleware 5 phases of middleware utilization Automate Rules for Manual Differentials Focus on Patient Safety Issues Enhance Laboratory Effectiveness Support Management Goals Unify Multi-site Practices
21 Five Phases of Middleware Support management goals Enhance laboratory effectiveness Focus on patient safety issues Automate rules for manual differentials Unify multi-site practices
22 Five Phases of Middleware Support management goals Enhance laboratory effectiveness Focus on patient safety issues Automate rules for manual differentials Unify multi-site practices
23 Differential? Instrument auto-verify Scan and release Manual LIS / EMR Minimal abnormal or normal Significant abnormal
24 Automate Rules for Manual Differentials Simply write rules for what the technologist does If they look up results in the computer If they compare results to previous studies If they base a decision on where the patient is or who their doctor is If they minimize or ignore certain results or certain instrument flags What are their algorithms for deciding whether a diff gets performed or not?
25 Automate Rules for Manual Differentials Quantitative numbers Ranges sensitive to age and gender Instrument flags Delta check to hold Delta check to release Delta check on instrument flags By physician By type of CBC By lab location By patient location By patient Elapsed time between specimen testing
26 ISLH Consensus Guidelines AGE Parameter Primary and/or Secondary and/or Tertiary Action 1 Neonate First sample Slide review CBC Parameter Primary and/or Secondary and/or Tertiary Action 1 WBC <4.0 or > 30.0 and Delta failed and < 3 days Slide review PLT <100 or >1000 and First time Slide review HGB <7g/dl or > 2g/dl above upper reference range for age and sex and First time Slide review RDW >22 and First time Slide review
27 ISLH Consensus Guidelines DIFFERENTIAL Parameter Primary and/or Secondary Action 1 No diff or incomplete diff Slide review Neut # <1.0 or > 20.0 and First time Slide review Lymph # >5.0 (adult) or >7.0 (<12 yrs old) and First time Slide review Mono # >1.5 (Adult) or >3.0 (<12 yrs old) and First time Slide review NRBC # any value and First time Slide review
28 ISLH Consensus Guidelines INSTRUMENT FLAGS Parameter Primary and/or Secondary and/or Tertiary Action 1 Suspect flag (except Imm G/B) Flag + and First time and Adult Slide review Dimorphic RBC Flag + and First time Slide review PLT clump flag Any count Check sample for clots Immature gran flag Flag + and Previous confirmed result and Positive delta fail for WBC Slide review Left shift flag Flag + Follow lab SOP Atypical lymphs Flag + and First time Slide review Blast flag Flag + and Previous confirmed result and Positive delta fail for WBC Slide review NRBC flag Flag + Slide review
29 Mayo Aqueduct Rules QUANTITATIVE FLAGS Tests Action Lo Hi Value Tests Held/Trapped Tests Pre-Transmitted Assigned Panels Hgb < X 6.1 RBC, Hgb, Hct, MCV, MCH, MCHC WBC, 5-pt diff, RDW, Plt CBC, CBCC, CBCN, CBC4/NC Plt < X 40.1 WBC, Plt WBC < X 1.0 WBC 5-pt diff, RBC, Hgb, Hct, MCV, MCH, MCHC, RDW 5-pt diff, RBC, Hgb, Hct, MCV, MCH, MCHC, RDW, Plt CBC, CBCN, CBC4/NC CBC, CBCN, CBC4/NC Plt Contains > R 39 WBC, Plt 5-pt diff, RBC, Hgb, Hct, MCV, MCH, MCHC, RDW CBC, CBCN, CBC4/NC
30 Mayo Aqueduct Rules INSTRUMENT FLAGS Value Tests Held/Trapped Tests Pre-Transmitted Assigned Panels Imm. Ne 2 5-pt diff CBC CBC, CBC4/NC Low Event # 5-pt diff CBC CBC, CBC4/NC Ly Blasts 5-pt diff CBC CBC, CBC4/NC Platelet Clumps CBC & diff None RBC Interference CBC WBC, 5-pt diff CBC, CBCN, CBC4/NC CBC, CBCC, CBCN, CBC4/NC, CBCCG Variant LY 5-pt diff CBC CBC, CBC4/NC
31 Mayo Aqueduct Rules DELTA CHECK Tests Action Lo Hi Value Tests Held/Trapped Tests Pre- Transmitted Assigned Panels Plt Exceeds Hold Delta (Current is both + & - 80%. New release You can choose one or the other or both) 80%/ 4 days CBC & diff None CBC, CBCC, CBCN, CBBCCG, CBC4/NC RDW Exceeds Release Delta > Location is not X 10%/ 7 days 17.5 Spec. Sta. RDW WBC, 5-pt diff, RBC, Hgb, Hct, MCV, MCH, MCHC, Plt CBC, CBC4/NC
32 Lab NE St. Marys (SMH) SMH Lab (ER, OR, ICUs) Lab NW Lab Kasson Methodist (MH) MH Lab (OR, ICUs) Lab Kenyon Lab Bldg Lab Bldg Lab Bldg Outpatient Clinics Gonda Lab (Chemo) Blood Draw Central Auto. Lab Heme Lab
33 Central Auto. Lab n=1719 March 19, 2008 Middleware auto-verify n= % LIS / EMR Trapped by Middleware: Quantitative CBC: 195 Quantitative Diff: 168 Instrument Flags: 302 Individual Patients: 6 Heme Lab n=315 18% 2% 6% 10% Instrument auto-verify n=42 Scan and release n=105 Manual diff n=168 13% 33% 54%
34 Middleware - Impact Instrument auto-verify Scan and release Manual: Normal / minimal Manual: Abnormal (significant) Pre-Middleware: Current: 40% 20% ~30% ~10% 82% 8% 2% 8% Within 3 months of implementation: Decreased 3.0 FTE TAT of Priority 1 CBC s: went from 50% to 85% released < 30 min. Median TAT of all CBC s went from 90 min. to 30 min. Average CBC time in central automated lab: <20 min.
35 Automate Rules for Manual Differentials CBC Chemotherapy Applied different rules for patients receiving chemotherapy for myeloma and lymphoma and certain leukemias The entire clinical question is: Are there enough platelets and neutrophils so that the hematologist can continue to give the next dose of chemotherapy?
36 Automate Rules for Manual Differentials CBC Chemotherapy (CBC-C) C) Created a new type of orderable CBC available only to the hematologists: CBC-C Clinical needs: The CBC is no longer a screening assay it is a therapeutic monitoring assay. An accurate diff is not a concern, just: are there PMN s and platelets? A rare blast or a slight left shift is not important Rapid turn-around around-time is the driving force
37 Automate Rules for Manual Differentials Separate auto-verify rules for the CBC-C WBC>99.9; Hgb<6.1; MCHC>37; BA%>5 5-part R flag; Interference flags; non-results Plt delta check Clinical awareness is important Cannot be used for other clinical scenarios Need to call the lab to convert the CBC to a real CBC if there are any clinical findings that raise other questions such as infection, etc.
38 Automate Rules for Manual Differentials Pre CBC-C ~150 CBC s per week from chemo unit Autoverify through Aqueduct 35% Average TAT: 20 min. vs. 2.5 hours Not a happy clinical group! CBC-C C implemented in 2001 Post CBC-C Autoverify: 88% TAT = 20 min from blood draw Audits: Neutropenia Thrombocytopenia Left shift RBC poik (non-specific) Rare blast (LEBR) Rare lymphoma or plasma cell ~1 CBC-C C converted to routine CBC per month
39 Five Phases of Middleware Support management goals Enhance laboratory effectiveness Focus on patient safety issues Automate rules for manual differentials Unify multi-site practices
40 Focus on Patient Safety Issues Why call it patient safety? In the hematology laboratory, true primary sentinel events are blessedly rare BUT: : Revised reports from labs do contribute to unnecessary clinical steps, which may lead to unnecessary patient events Every lab needs to look at all their revised reports and near misses. Why did they happen? What was wrong with the process? Until you collect the info, you will underestimate the severity of the issue
41 Focus on Patient Safety Issues Revised reports and near misses Revised diff counts (instrument or tech) After pathologist review of a bone marrow After tech review of a subsequent PB smear After a call from a clinician Revised platelet count due to clotted specimens or EDTA-associated clumping After tech review of a subsequent PB smear After a call from a clinician Dependency on sticky notes and memory
42 Focus on Patient Safety Issues Revised reports and near misses (con t con t.) Didn t follow through per SOP (memory) Did a scan and release instead of a manual diff Forgot to have a second review by senior tech or MD Etc. Manual reporting / clerical error (direct interface) Mixing up slides and paperwork (barcodes)
43 Focus on Patient Safety Issues Individual patients act like individuals they don t always follow the rules for the group. Let s call our patient: Mrs. Johnson Blasts may be missed on follow-ups Lymphoma cells may be missed on follow-ups Morphologic features may be difficult to interpret EDTA platelet clumpers create problems Red cell agglutination create problems Clinician or pathologist need specific follow-up on Mrs. Johnson Protocol/clinical trial requirements
44 Focus on Patient Safety Issues Middleware can help Immediately in the lab can create a rule to trap the next sample that comes through from Mrs. Johnson A time line is added to the rule; e.g., expires in one month or three months Doesn t matter where in the system Mrs. Johnson walks into main clinic, ER, outlying clinic, etc.: same outcome for the CBC
45 Focus on Patient Safety Issues Pre- Mrs Mrs.. Johnson Revised differentials 2.5 A events / mo. Communicate by sticky notes and s Post- Mrs Mrs.. Johnson Revised differentials <1 A event / mo. 5 to 10 Mrs. Johnson rules in place at any given time < 2 hrs. from request to being live
46 Five Phases of Middleware Support management goals Enhance laboratory effectiveness Focus on patient safety issues Automate rules for manual differentials Unify multi-site practices
47 Enhance Laboratory Effectiveness Use middleware to streamline the presentation and flow of data from instrument to workstation regardless of where data was acquired Minimize the number of manual steps between instrument and slide review Blends with patient safety issues
48 Enhance Laboratory Effectiveness Use middleware to make the lab paperless At each workstation: Transmit scatterplots to any workstation Make all CBC/diff data easily visible Apply color coding to aid visual recognition Visually see trapped vs. released data Display invoked rules for trapped data Multiple ways to review old data By CBC date By each analyte
49
50
51
52
53 Enhance Laboratory Effectiveness Lab continues to run if LIS is down Use rules as SOP reminders E.g.: new employee can t report out schistocytes without 2 nd review All new adult lymphocytoses needs MD review All blasts >1% need initial MD review Disease processes Set frequency of review after initial diagnosis of a disease: e.g., CLL, MDS, etc.
54 Enhance Laboratory Effectiveness The instrument s QC package (1( 2s N=2 or 3) is not optimal for each of the CBC s components. A high false rejection rate breeds complacency: LH750 Sigma Metric QC Rule Hgb s N=3 WBC s N=3 RBC s N=3 Plt s N=3 Can you use middleware as your QC manager?
55 Five Phases of Middleware Support management goals Enhance laboratory effectiveness Focus on patient safety issues Automate rules for manual differentials Unify multi-site practices
56 Support Management Goals Is there laboratory information that cannot be gathered through routine reports? Technologist productivity Type of cases released by technologist Number and type of cases trapped by each rule Monitor utilization of rules Identify new clinical scenarios for potential new rules
57 Technologist Productivity Avg. PB cases / shift A C E G I K M O Q S U W Y AA CC
58 Differential? Instrument auto-verify Scan and release Manual LIS / EMR Minimal abnormal or normal Significant abnormal
59 Technologist Productivity Avg. PB cases / shift E R S W X CC DD Scan Manual
60 Five Phases of Middleware Support management goals Enhance laboratory effectiveness Focus on patient safety issues Automate rules for manual differentials Unify multi-site practices
61 Future Needs: Unify Multi-site Practices Multiple sites within a hospital/clinic Multiple hospitals and clinics within an organization local, regional, national May have different instrumentation Different clinical needs at each site Different patient characteristics at each site Not all sites may do manual differentials May or may not have a common EMR
62 Future Needs: Unify Multi-site Practices Middleware offers you a common language through which laboratories can communicate Middleware offers you a starting point for standardization / integration of your medical practice
63 Middleware Conclusions Before you purchase / implement: Model your lab practice to understand where you might benefit from middleware and to what extent Keep in mind the Value Equation both quality and costs can be improved with middleware Envision the coordinated roles that your instrument, LIS, and potential middleware system will play in your lab practice Instrument and LIS might be sufficient in some labs Work with your IT people to understand their needs and their willingness to help provide support in the lab
64 Middleware Conclusions Automate rules for differentials this is the easy part! Benefits include: Reduce costs / FTE s Improve TAT Improve employee satisfaction Improve accuracy of differential results Challenge your concept of the CBC and diff and think differently about specific patient populations and their needs
65 Middleware Conclusions Focus on patient safety issues. Every lab needs to look at all their revised reports and near misses. Why did they happen? What was wrong with the process? Use middleware to fill in gaps in your patient safety processes: The Mrs. Johnson Rules SOP and disease-specific specific Pop-Up reminders for the techs
66 Middleware Conclusions Enhance laboratory effectiveness Create the paperless lab Ensure the ideal screen presentations of data Minimize the steps between CBC analyzer and the microscope/work station Improve your QC approach in the lab Support management goals Middleware is another source of information about your laboratory Unify multi-site practices A common language to cross-communicate communicate with other labs A starting point for standardization / integration of your multi- site laboratory practice
67 Balance Balance? Achieved! Clinical Needs and vs. Laboratory Reality Outcomes Satisfaction TAT Accuracy Management Patient safety Resources Costs Middleware!
68 Thank You!
Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.
Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,
More informationHematology Morphology Critique
Survey Slide: History: 60-year-old female presenting with pneumonia Further Laboratory Data: Hgb : 90 g/l RBC : 2.92 10 12 /L Hct : 0.25 L/L MCV : 87 fl MCH : 30.8 pg MCHC : 355 g/l RDW : 17.7 % WBC :
More informationXE-2100 Automated Hematology System. Fast, Accurate, Dependable
XE-2100 Automated Hematology System Fast, Accurate, Dependable Advanced Technology Solutions to Meet your Lab s Needs Even with these challenges, the need for hematology testing has remained steady or
More informationAutomation is Here. Now How Do You Handle All the Data? Swedish Covenant Hospital Lab. Life IS Good
Automation is Here Now How Do You Handle All the Data? Susan Dawson, MBA, MT (ASCP) Swedish Covenant Hospital Chicago, IL Swedish Covenant Hospital Lab Automation in 2002 (Chem/IA) Autovalidation for Chemistry
More informationReshaping compact automation. XN-Series Automated Hematology Systems
Reshaping compact automation XN-Series Automated Hematology Systems Small, Smart, Compact Automation It s an approach to hematology testing that s never been done before. An approach that gives all laboratories
More informationPentra DX Nexus. Process efficiency in Hematology
Pentra DX Nexus Process efficiency in Hematology Pentra DX Nexus Be productive and flexible 120 samples per hour 28 parameters Automatic reflex testing Automatic validation of results Integrated cytology
More informationNEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010
NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010 Slide 081 Available data: 72 year-old female Diagnosis: MDS to AML WBC 51.0 x 10 9 /L RBC 3.39 x 10 12 /L
More informationGoing Beyond Laboratory Automation: Do Less Accomplish More. Swedish Covenant Hospital
Going Beyond Laboratory Automation: Do Less Accomplish More Susan Dawson, MBA, MT(ASCP) Swedish Covenant Hospital Chicago, IL Swedish Covenant Hospital Open Heart Oncology Birthing Unit Community Outreach
More informationCentraLink Data Management System
www.siemens.com/diagnostics CentraLink Data Management System Delivering quality lab results faster for better patient care Answers for life. CentraLink Data Management System Delivering quality lab results
More informationLaboratory Computer Systems
LAP Audioconference Laboratory Computer Systems October 21, 2009 Bruce A. Beckwith, MD, FCAP 2009 College of American Pathologists. Materials are used with the permission of the faculty Learning Objectives
More informationDepartment of Pathology and Laboratory Medicine Capital District Health Authority Nova Scotia
Department of Pathology and Laboratory Medicine Capital District Health Authority Nova Scotia Doc #: 10902 Section: \\Management System\PLM\Point of Care Testing\CBC Diff\ Document Owner: ES Team Lead
More informationHAEMATOLOGY LABORATORY
HAEMATOLOGY LABORATORY Head of Unit : Dr Raudhawati Osman Phone : +603-26155281 Email : raudhaosman@yahoo.com 1. INTRODUCTION The Haematology Unit, Department of Pathology, HKL provides tertiary diagnostic
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationBC-5800. Auto Hematology Analyzer
BC-5800 Auto Hematology Analyzer BC-5800 Auto Hematology Analyzer 5-part differentiation, 29 parameters, 2 histograms + 2 scattergrams Up to 90 samples per hour Laser scatter + Chemical dye + Flow cytometry
More information2009 LAP Audioconference Series. Laboratory Computer Systems
2009 LAP Audioconference Series Objectives: After participating in this audioconference you will be able to: Describe the requirements for validating computer interfaces Understand the principles for validating
More informationPathology No: SHS-CASE No. Date of Procedure: Client Name Address
TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,
More informationHumaCount System Line A Better Way to Connect. A Better Way to Work.
HumaCount System Line A Better Way to Connect. A Better Way to Work. > Integration into hospital management system > 2D barcode target transfer range > CoreLab DX Hematology Thousands of HumaCounts Installed
More informationMANUAL WBC LAB OBJECTIVE
MANUAL WBC LAB OBJECTIVE The student will be able to perform, within K20% accuracy as compared to the automated result, five manual white blood cell counts using the Unopette system. PRINCIPLE Free-flowing
More informationJennifer G. Collins, RN Children s Hospital of Chicago
Jennifer G. Collins, RN Children s Hospital of Chicago Review the importance of consultation with the stem cell transplant team Review criteria to begin harvest Review ways to modify a harvest procedure
More informationCytogenetics for the Rest of Us: A Primer
Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen
More informationQUALITY CONTROL (QC) INFORMATION AND TROUBLESHOOTING GUIDE HEMATOLOGY
QUALITY CONTROL (QC) INFORMATION AND TROUBLESHOOTING GUIDE HEMATOLOGY This document is not intended to replace the information in your Instructions for Use Manuals (IFU). Information in the Instructions
More informationPreparation of Blood Films
Preparation of Blood Films Principle: Blood film enables us to evaluate WBC, RBC, and PLT morphology, also, allows us to perform differential WBC count, furthermore estimation of WBC and platelets counts
More informationExercise 9: Blood. Readings: Silverthorn 5 th ed, 547 558, 804 805; 6 th ed, 545 557, 825 826.
Exercise 9: Blood Readings: Silverthorn 5 th ed, 547 558, 804 805; 6 th ed, 545 557, 825 826. Blood Typing The membranes of human red blood cells (RBCs) contain a variety of cell surface proteins called
More informationYoung fetus: site of hematopoiesis together with the liver and bone marrow. Hgb WBC >----------< Plt Hct. Retic =
Learning Objectives At the completion of this program, the participants will be able to: 1. Identify the components of the CBC and Differential and their clinical implications. 2. Identify normal pediatric
More informationMarch 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,
Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
More informationHepatitis C. Laboratory Tests and Hepatitis C
Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationThe Treatment of Leukemia
The Treatment of Leukemia Guest Expert: Peter, MD Associate Professor of Hematology Director, Yale Cancer Center Leukemia Program www.wnpr.org www.yalecancercenter.org Hi, I am Bruce Barber and welcome
More informationSentara Healthcare EMR: Our Journey. Bert Reese, CIO and Senior Vice President
Sentara Healthcare EMR: Our Journey Bert Reese, CIO and Senior Vice President Sentara Healthcare 123-year not-for-profit mission 10 hospitals; 2,349 beds; 3,700 physicians on staff 10 long term care/assisted
More informationEDUCATIONAL COMMENTARY RED BLOOD CELLS AND WHITE BLOOD CELLS IN URINALYSIS
URINALYSIS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing
More informationLaboratory 12 Blood Cells
Laboratory 12 Blood Cells Objectives: Identify microscopically each of the following: erythrocytes (red blood cells or RBCs), the five types of leukocytes (white blood cells or WBCs), and thrombocytes
More informationMonoclonal Gammopathy of Undetermined Significance (MGUS) Facts
Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts Normal plasma cells (a type of white blood cell) produce antibodies (also known as immunoglobulins) which help fight infection. Each type
More informationReference Range: 0.5-1.6 mmol/l (arterial) 0.7-2.1 mmol/l (venous) CPT Code: 83605
LACTIC ACID Fasting, arterial specimen preferred. Please note whether arterial or venous. 0.5 ml heparinized plasma. Green top or PST must be drawn, placed on ice, and spun within 15 minutes. Immediately
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not
More informationMANUAL PLATELET COUNT
MANUAL PLATELET COUNT LAB OBJECTIVE The student will be able to perform, within K20% accuracy as compared to the automated result, five manual platelet counts using the Unopette system. and the light microscope.
More informationFacing Healthcare Administration Challenges
Facing Healthcare Administration Challenges Healthcare provider administration tasks, are facing different types of challenges. The delivery of health care services is the most visible part of any health
More informationExplanation of your PAP smear
Explanation of your PAP smear Approximately 5-10% of PAP smears in the United States are judged to be abnormal. Too often, the woman who receives this news worries that she already has, or will develop,
More informationGeorgia Northwestern Technical College Practical Nursing Program CLINICAL DAILY ASSESSMENT WORKSHEET FOR MODULES I-IV STUDENT: CLINICAL INSTRUCTOR:
Georgia Northwestern Technical College Practical Nursing Program CLINICAL DAILY ASSESSMENT WORKSHEET FOR MODULES I-IV STUDENT: CLINICAL INSTRUCTOR: CLINICAL UNIT: ASSIGNMENT DATES: PATIENT (last initial):
More informationLeukaemia and lymphoma what s the difference?
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk Leukaemia and lymphoma what s the difference? This is a difficult question to answer simply but it is one that is often
More informationSystems of Measurement
Systems of Measurement Course Principles of Health Science Unit X Vital Signs Essential Question What s math got to do with it? TEKS 130.202 (c)1a, 1B, 1D Prior Student Learning Basic understanding of
More informationLaboratory Studies in the Diagnosis of Iron Deficiency, Latent Iron Deficiency and Iron Deficient Erythropoiesis
Laboratory Studies in the Diagnosis of Iron Deficiency, Latent Iron Deficiency and Iron Deficient Erythropoiesis General Comments The laboratory studies listed below are helpful in the diagnosis and management
More informationYvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI
Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI Overview of Hematology, http://www.nu.edu.sa/userfiles/mhmorsy/h
More informationLeveraging your lab s data is essential in the new marketplace. Find out where to begin and how to succeed.
Clinical Informatics in the Laboratory: Leveraging your lab s data is essential in the new marketplace. Find out where to begin and how to succeed. Labs have a unique opportunity to become leaders in patient
More informationfor Leucocyte Immunophenotyping Leukaemia Diagnosis Interpretation All Participants Date Issued: 08-September-2014 Closing Date: 26-September-2014
for Leucocyte Immunophenotyping Leukaemia Interpretation All Participants Participant: 4xxxx Trial No: 141502 Date Issued: 08-September-2014 Closing Date: 26-September-2014 Trial Comments This was an electronic
More informationIf your doctor has ordered laboratory tests, it s natural
A Patient s Guide to Clinical oratory Testing at Kingman Regional Medical Center If your doctor has ordered laboratory tests, it s natural to have questions about why and how the tests are performed. This
More informationPut all your results in one basket. Orchard Pathology simplifies the complexities of clinical, molecular, and pathology testing and reporting.
Put all your results in one basket. Orchard Pathology simplifies the complexities of clinical, molecular, and pathology testing and reporting. Designed for the Comprehensive Pathology Laboratory Orchard
More informationEDUCATIONAL COMMENTARY - GRANULOCYTE FORMATION AND CHRONIC MYELOCYTIC LEUKEMIA
LEUKEMIA Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing Education
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationThrombin Formation for Children on Lovenox. Steven Ignell, BA
Thrombin Formation for Children on Lovenox Steven Ignell, BA Definitions Anticoagulation Historically this refers to inhibiting thrombin formation Measured by PTT, INR, anti-xa Hypo and hypercoagulation
More informationUniCare Professional Reimbursement Policy
UniCare Professional Reimbursement Policy Subject: Laboratory and Venipuncture Services Policy #: UniCare 0029 Adopted: 02/02/2010 Effective: 04/05/2016 Coverage is subject to the terms, conditions, and
More informationAcute myeloid leukaemia (AML) in children
1 61.02 Acute myeloid leukaemia (AML) in children AML can affect children of any age, and girls and boys are equally affected. Leukaemia Acute myeloid leukaemia (AML) FAB classification of AML Causes of
More informationABO-Rh Blood Typing Using Neo/BLOOD
ABO-Rh Blood Typing Using Neo/BLOOD Objectives Determine the ABO and Rh blood type of unknown simulated blood samples. Prepare a simulated blood smear. Examine a prepared blood smear under the microscope
More informationintroducing pathx. The Mouse Driven With Pathology Labs.
T h e n e w p at h f o r p at h l a b s introducing pathx. The Mouse Driven LIS That s Clicking With Pathology Labs. PathX is the most advanced laboratory information system for anatomic pathology. Our
More informationMinneapolis User Group Meeting
Minneapolis User Group Meeting September 25, 2012 DSM - Bill Troup FSRs - Linda Fog & Quirin Matthys Agenda What s new in Sysmex Services Our Support Quality Our Service Strategy Investment in Technology
More informationWHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?
WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? Which test should be submitted? The answer to this depends on the clinical signs, and the diagnostic question you are asking. If
More informationEXERCISE 5: ERYTHROCYTES SEDIMENTATION RATE - ESR, SED RATE
EXERCISE 5: ERYTHROCYTES SEDIMENTATION RATE - ESR, SED RATE Textbook: Skills: None 10 points Objectives: 1. State the principle of the Erythrocytes Sedimentation Rate - ESR. 2. List two factors which may
More informationUNIVERSITY OF CONNECTICUT HEALTH CENTER CORRECTIONAL MANAGED HEALTH CARE POLICY AND PROCEDURES FOR USE WITHIN THE CONNECTICUT DEPARTMENT OF CORRECTION
UNIVERSITY OF CONNECTICUT HEALTH CENTER CORRECTIONAL MANAGED HEALTH CARE POLICY AND PROCEDURES FOR USE WITHIN THE CONNECTICUT DEPARTMENT OF CORRECTION NUMBER: P 1.01 Page 1 of 1 PATIENT SAFETY SYSTEM/PSS:
More informationA Focus on Effective Test Utilization to Demonstrate Lab Value in the New Healthcare Model
A Focus on Effective Test Utilization to Demonstrate Lab Value in the New Healthcare Model Kim Futrell, MT (ASCP) Products Marketing Manager Orchard Software Corporation Page 1 Objectives Understand the
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationHematology Reagents and Controls Our products for your critical process
Part of a pure process Hematology Reagents and Controls Our products for your critical process 2 Reagents you can count on Mallinckrodt Baker s chemical expertise and 30 years of experience are the foundation
More information141 The Role of the Laboratory Director: Responsibilities, Expectations and Challenges. Ronald Weiss MD, MBA
141 The Role of the Laboratory Director: Responsibilities, Expectations and Challenges Ronald Weiss MD, MBA 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe, Ste.
More informationThe Human Experiment- Electronic Medical/Health Records
The Human Experiment- Electronic Medical/Health Records Patient safety is one of the primary stated intentions behind the push for computerized medical records. To the extent illegible handwriting leads
More informationSuffolk County Community College School of Nursing NUR 133 ADULT NURSING I
Suffolk County Community College School of Nursing NUR 133 ADULT NURSING I Page # 1 Instructions for students: Case study # 1 For this lab, you are planning to provide care to the following client: CB
More informationData Management. Shanna M. Morgan, MD Department of Laboratory Medicine and Pathology University of Minnesota
Data Management Shanna M. Morgan, MD Department of Laboratory Medicine and Pathology University of Minnesota None Disclosures Objectives History of data management in medicine Review of data management
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationPhlebotomy Handbook Blood Collection Essentials Seventh Edition
Phlebotomy Handbook Blood Collection Essentials Seventh Edition Diana Garza Kathleen Becan-McBride Chapter Four The Cardiovascular System Introduction Circulatory system is a transport system. Contributes
More informationLab 02: Blood Cytology (20 points)
Pierce College Putman/Biol 242 Name: Lab 02: Blood Cytology (20 points) Reference: Marieb & Mitchell 9 th Ed: 29A (Activities 1, 2, 3, 4, 7); 10 th Ed: Exercise 29 (Activities 1, 2, 3, 4, 7). Pierce College
More informationName of Child: Date: About Blood Cells
The Emily Center About Blood Cells Procedure/Treatment/Home Care Si usted desea esta información en español, por favor pídasela a su enfermero o doctor. #736 Name of Child: Date: About Blood Cells Blood
More informationCardiovascular System. Blood Components
Cardiovascular System Blood Components 1 Components of Blood Formed elements: erythrocytes, leukocytes, platelets Plasma: water, proteins, other solutes The components of blood can be divided into two
More informationUniversity Hospital Ulm Ulm, Germany. Prof. Dr. Dr. Dr. h.c. Max G. Bachem, Director Kerstin Stöhrer, Technical Supervisor
University Hospital Ulm Ulm, Germany Prof. Dr. Dr. Dr. h.c. Max G. Bachem, Director Kerstin Stöhrer, Technical Supervisor The University Hospital Ulm was founded in 1982. In 30 years it has built an enviable
More informationILLINOIS DEPARTMENT OF CENTRAL MANAGEMENT SERVICES CLASS SPECIFICATION CLINICAL LABORATORY TECHNICIAN SERIES
ILLINOIS DEPARTMENT OF CENTRAL MANAGEMENT SERVICES CLASS SPECIFICATION CLINICAL LABORATORY TECHNICIAN SERIES CLASS TITLE POSITION CODE CLINICAL LABORATORY TECHNICIAN I 08215 CLINICAL LABORATORY TECHNICIAN
More informationSTANDARD BLOOD PRODUCTS AND SERVICES
STANDARD BLOOD PRODUCTS AND SERVICES Policy NHP reimburses contracted providers for the medically necessary administration (transfusion) of blood and standard blood products. Prerequisites Authorization,
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationHow to Verify Performance Specifications
How to Verify Performance Specifications VERIFICATION OF PERFORMANCE SPECIFICATIONS In 2003, the Centers for Medicare and Medicaid Services (CMS) updated the CLIA 88 regulations. As a result of the updated
More informationPatient Centered Medical Home: An Approach for the Health Plan
: An Approach for the Health Plan By Marissa A. Harper and JoAnn E. Balara Excellence in healthcare consulting The Medical Home Concept Works Recent Medicare demonstration projects on Patient Centered
More informationAcute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
More informationKEY CHAPTER 14: BLOOD OBJECTIVES. 1. Describe blood according to its tissue type and major functions.
KEY CHAPTER 14: BLOOD OBJECTIVES 1. Describe blood according to its tissue type and major functions. TISSUE TYPE? MAJOR FUNCTIONS connective Transport Maintenance of body temperature 2. Define the term
More informationIntelligent laboratory management Delivered by cobas IT middleware
For technical specifications and additional information please see the enclosed datasheets. Intelligent laboratory management Delivered by cobas IT middleware To arrange a meeting or demonstration to learn
More informationControversies in the management of patients with PMF 0/1
State of the art treatments of patients with MPNs Turracher Höhe 2010 Controversies in the management of patients with PMF 0/1 Heinz Gisslinger Medical University of Vienna Divison for Hematology, Vienna
More informationUniversity of Pennsylvania RESEARCH Subject Informed Consent Form AND RESEARCH SUBJECT HIPAA AUTHORIZATION
University of Pennsylvania RESEARCH Subject Informed Consent Form AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: Evaluating the impact of cocaine use and HIV infection in arterial wall inflammation
More informationDoes chronic lymphocytic leukemia increase the risk of osteoporosis?
Does chronic lymphocytic leukemia increase the risk of osteoporosis? Amrita Desai, MD Internal Medicine Residency Program Adam Olszewski, MD Department of Hematology and Oncology Memorial Hospital of Rhode
More informationRethinking Radiology Workflow Automating Workflow Processes
Available at: http://www.corepointhealth.com/whitepapers/rethinking-radiology-workflow Rethinking Radiology Workflow Automating Workflow Processes Executive Summary Imaging centers are targeting both internal
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More information2015 HEDIS/CAHPS Effectiveness of Care Report for 2014 Service Measures Oregon, Idaho and Montana Commercial Business
2015 HEDIS/CAHPS Effectiveness of Care Report for 2014 Service Measures Oregon, Idaho and Montana Commercial Business About HEDIS The Healthcare Effectiveness Data and Information Set (HEDIS 1 ) is a widely
More informationProcessing & Utilization of Cord Blood for Transplant
Processing & Utilization of Cord Blood for Transplant 2010-Jan Jan-15 Nicole L. Prokopishyn, PhD HPC Processing Laboratory Director Calgary Laboratory Services Overview Cord Blood Processing Pre-Freeze
More informationGlobal Lab for Innovation
Global Lab for Innovation Innovation Profile IT for Cost-Effective Decision Making Cedars-Sinai Health System Clinical decision support and the Choosing Wisely guidelines are built into an Electronic Medical
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationDepartment of Transfusion Medicine and Immunohematology
Department of Transfusion Medicine and Immunohematology Activities Transfusion medicine is a multidisciplinary area concerned with the proper use of blood and blood components in the treatment of human
More informationA LEAN SIX SIGMA APPROACH TO CONTINUOUS QUALITY IMPROVEMENT IN THE TEXAS NEWBORN SCREENING PROGRAM
A LEAN SIX SIGMA APPROACH TO CONTINUOUS QUALITY IMPROVEMENT IN THE TEXAS NEWBORN SCREENING PROGRAM PATRICIA HUNT V. Telles, T. Odoms, P. Trevino Gonzales, A. Vinyard, L. Cao, S. Tupy, B. Reilly, P. Hunt,
More informationThe Evolving Comparative Analytics Market:
The Evolving Comparative Analytics Market: Benchmarking Key Business Metrics Against Peers to Reduce Risk, Pinpoint Areas for Improvement, and Optimize Performance March 2013 UNDERSTANDING THE OPPORTUNITY
More informationChristine M. Cunningham Associate Professor New York Chiropractic College 2360 Route 89 Seneca Falls, New York 13148 315-568-3122 ccunning@nycc.
Christine M. Cunningham Associate Professor New York Chiropractic College 2360 Route 89 Seneca Falls, New York 13148 315-568-3122 ccunning@nycc.edu EDUCATION Master of Science in Health Sciences Education,
More informationHow To Collect A Leukapheresis Collection
Leukapheresis Collection Insights in Unstimulated Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving a Combination of Autologous Immunotherapy (AGS-003) and Sunitinib: From the Ongoing
More informationMy Sister s s Keeper. Science Background Talk
My Sister s s Keeper Science Background Talk Outline Acute promyelocytic leukemia (APL) APL Treatment Savior Siblings In vitro fertilization (IVF) Pre-implantation Genetic Diagnosis (PGD) Risks of donating
More informationCommunity Physicians of Indiana Engineering Forms to Improve Quality of Care and Physician Efficiency Ryan Houghton, M.D.
Community Physicians of Indiana Engineering Forms to Improve Quality of Care and Physician Efficiency Ryan Houghton, M.D. Disclosure No additional relationships or conflicts of interest besides employment
More informationCalibration Verification
Calibration Verification INTRODUCTION On January 24, 2003, the Centers for Medicare and Medicaid Services (CMS) published updated laboratory regulations that became effective April 24, 2003. Included in
More informationPlatelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015
Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. Today our topic looks at hereditary platelet
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More information